Evogene Ltd

Evogene Q1 2026 results: loss per share, 86% revenue drop, yet ChemPass AI™ & Google Cloud partnership fuel growth in pharma & agri markets – watch investor outlook and future earnings.

Evogene Ltd. faces a 180‑day Nasdaq compliance deadline to lift its bid price to $1.00 and avoid delisting, while its AI‑driven biotech tech aims to tap a booming ag‑sector market.

Evogene Ltd, a pioneering biotechnology company, leverages computational biology and AI to drive innovation in human health and agriculture, despite facing financial challenges and volatility in the market.